Osteoporosis Database

Osteoporosis is a common skeletal disorder that causes a decrease in bone mass and density, causing bones to become abnormally thin (osteopenic), weakened, and easily broken (fractured). Drug therapies for osteoporosis include bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid), hormone replacement therapy (estrogen), selective estrogen receptor modulator (raloxifene), calcitonin, and parathyroid hormone (teriparatide, PTH1-84). Several newer therapies (such as lasofoxifene, bazedoxifene, odanacatib, denosumab) are in development or have recently received regulatory approval.

The current release of our database focuses on prevention and treatment of osteoporosis in postmenopausal woman. The objective of the database is to extract all relevant changes in bone mineral density, biochemical markers of bone turnover, fracture risk, and safety parameters after treatment with bisphosphonates, estrogens, SERMs, calcitonin, parathyroid hormone, newer therapies or their combinations.

The current release of our Osteoporosis Database includes data from 95 references, representing information on 78 unique trials, 256 unique treatment arms and about 108,000 patients. Download an information sheet for the Osteoporosis database.